VASCULAR SURGICAL ASPECT OF DIABETIC FOOT (42-45)

DOI: 10.31618/ESU.2413-9335.2019.1.60.42-45

Дата публикации статьи в журнале: 2019/04/21

Название журнала: Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале, Выпуск: 60, Том: 1, Страницы в выпуске: 42-45

Автор: Kostov O. H.
assistant, Medical University - Plovdiv,

Анотация: Diabetes continues to grow globally and to spend extremely large resources in the health sector. One of the main factors for the incidence of diabetes is diabetic foot. Necrotic changes in the latter are a complex problem. Ischemia, neuropathy and infection are the three pathological components that lead to complications and often occur together as etiological triad. Neuropathy and ischemia are initiating factors, most often in tandem as neuroischemia until the infection is more a consequence. The role of peripheral arterial disease in diabetic foot long underestimated since typical ischemic symptoms are less common in diabetic patients with ischemia than in nondiabetic patients. Each necrosis diabetic foot must wake suspected vascular disease until proven otherwise. Early referring the patient to a specialist, noninvasive vascular testing, diagnosis and intervention are crucial for the healing of necrosis and for the prevention of amputations, timing is crucial because a window in which we can achieve wound healing and save limbs often can be omitted.

Ключевые слова: diabetic foot, neuroischemia,revascularization,amputation,

Данные для цитирования: Kostov O. H. . VASCULAR SURGICAL ASPECT OF DIABETIC FOOT (42-45) // Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале. Медицинские науки. 2019/04/21; 60(1):42-45. 10.31618/ESU.2413-9335.2019.1.60.42-45

Скачать в формате PDF

Список литературы: 1. Bostrom P. Wu.J. Jedrychowske MP, et al A PGCI-α-dependent myokine that drives brown-fat-like development of white fat ana thsmiogenesis. Nature. 2012;481:463-468 2. Conway B, Mille RG. Costacou T. ei al. Adiposity and mortality in type 1 diabetes. Int Obes (Loud). 2009;33:796-805 3. Costacou T, Evans RW, Orchard TJ. Highdensity lipoprotein cholesterol in diabetes: is higher always better? J Clin Lipidol. 2011:5:387-394. 4. Costacon T, Ferrell RE, Orchard , J. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes. 2008;57:17021706. 5. Dabelea D, Kinney G, Snell-Bergeon JK. Hokanson JE. Eckel RH, Ehrlich J, Garg S, Наmmаn RF. Rewers M. Coronary Artery Calcification in Type i Diabetes Study. Effect of type I diabetes on the gender difference in coronary artery calcification: a role for insulin resistance'' The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003;52(11):2833-2839. 6. Darabian S, Backland JY. Cleary PA. Sheidaec N, Bebu I, Lachin JM. Bndoff MJ; DCCT/EDIC Research Group. Significance of epieardial and intrathoracic adipose tissue volume among type 1 diabetes patients in the DCCPEDIC: A pilot study. PLoS One. 2016: 11(7):e0159958. 7. De Ferranti SD, de Boer IH, Fonseca V. et. al. Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific State- ment From the American Hears Association and American Diabetes Association. Diabetes Care. 2014:37.2843-2863. 8. Du Bose SM Flermann JM. Tamboriane WV, Beck RW, Dost A. DiMeglio LA, Schwab KO, Holl RW, Hofer SE Maahs DM; Type 1 Diabetes Exchange Clinic Network and Diabetes Prospective Follow-up Registry. Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States. J Pediatr 2015 Sep;167(3):627-32.c 1-4. 9. Tapes D, Lao J, Carlssoo PO. Increased levels of irisin in people with long-standing Type 1 diabetes. Diabet Med. 2015 Sep;32(9): 1172-76. 2007; 12:175-194. 10. Hall K, Liu KJ, Sima AA, Wiley JW. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol. 2001 ;86:760-770. 11. Varkonyi T. Putz Z, Keresztcs K. Martos T. Lengyel C, Stirban A, Jermendy G, Kempler P. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pltarin Des. 2013;19(27):4981-5007. 12. Boulton AJ, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metal) Res Rev. 2013;29(5):327-33. 13. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol. 2004;3(3): 173-89. 14. Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers, hit J Burns Trauma. 2011; 1 (I ):68-76. 15. Bril V, Hirose T, Toniioka S, Buchanan R; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care. 2009:32(7): 1256-60. 16. Schcmtnel KE, Padiyara RS, D‘SouzaJJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review ../Diabetes Complications. 2010;24(5):354-60. 17. Bansal D, Badhan Y, Gudala K, Schilano F. Ruboxistaurin for the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review of Randomized Clinical Trials. Diabetes Metab J. 2013;37(5):375-384. 18. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M. Baker JR, Kcech AC: FIELD study- investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mcllitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009:373(9677): 1780-8. 19. Snell EE, Strong FM, Peterson WII. Growth factors for bacteria. VI: Fractionation and properties of an accessory factor for lactic acid bacteria. Biochem J. 1937:31 (10): 1789-1799. 20. Reed LJ, DeBusk BG, Gunsalus IC, Hornbcrger CS Jr. Cristalline alpha-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science. 1951; 114(2952):93-94.